Anatabine Supplementation Decreases Thyroglobulin Antibodies in Patients With Chronic Lymphocytic Autoimmune (Hashimoto's) Thyroiditis: A Randomized Controlled Clinical Trial

作者：Schmeltz Lowell R; Blevins Thomas C; Aronoff Stephen L; Ozer Kerem; Leffert Jonathan D; Goldberg Marc A; Horowitz Barry S; Bertenshaw Richard H; Troya Pedro; Cohen Amy E; Lanier Ryan K^*; Wright Curtis

来源：Journal of Clinical Endocrinology & Metabolism, 2014, 99(1): E137-E142.

DOI：10.1210/jc.2013-2951

Context: Hashimoto's thyroiditis is less prevalent in tobacco smokers. Anatabine, an alkaloid found in Solanaceae plants including tobacco, has been reported to ameliorate a mouse model of Hashimoto's thyroiditis.
Objective: The effects of anatabine in patients with Hashimoto's thyroiditis were studied.
Design, Setting, Patients, and Intervention: This was a double-blind, randomized, placebo-controlled multisite study. A total of 146 patients (70 treated with anatabine and 76 with placebo) completed the study. Approximately 50% of patients in each group were taking levothyroxine. Anatabine lozenges (9-24 mg/d) or placebo, each containing vitamins A and D-3, were administered orally 3 times a day for 3 months.
Main Outcome Measures: Serum thyroperoxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) levels were assessed. Safety was assessed through adverse events, clinical laboratory evaluations, and vital sign measurements.
Results: Anatabine-treated patients had a significant reduction in absolute serum TgAb levels from baseline by study end relative to those receiving placebo (P = .027); however, there were no significant changes or differences in treatment group means for TPOAb or TgAb levels. Mean +/- SD TgAb values decreased by 46.2 +/- 101.1 and 3.9 +/- 83.9 World Health Organization units for the anatabine and placebo groups, respectively. Significantly more patients had a >20% drop in TgAb levels in the anatabine than placebo group (P = .023). Overall, the anatabine supplement was safe and well tolerated, although significantly (P < .05) more patients in the anatabine group reported adverse events.
Conclusions: These results demonstrate an immunological effect of anatabine on TgAb levels. Further studies are warranted to determine the longer-term effects and possible actions of anatabine on the course of Hashimoto's thyroiditis.

• 出版日期2014-1